# US 2014/0154799 A1 · Method of obtaining circulating cancer cell populations, associated cellular compositions and methods of using same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0154799 A1 - Document ID: US20140154799A1 - Status: Published application - Kind: A1 - Application number: 14/097,605 - Filed: 2013-12-05 - Published: 2014-06-05 - Earliest claimed: 2012-12-05 - Assignees: The Royal Institution for the Advancement of Learning/Mcgill University - Applicants: The Royal Institution for the Advancement of Learning/Mcgill University - Inventors: Catalin MIHALCIOIU; Richard KREMER; Michael SEBAG; Ramy SALEH; Jiarong LI - Web page: https://patentgrep.com/patent/US20140154799A1 ## CPC - C12N 5/0694: {Cells of blood, e.g. leukemia cells, myeloma cells} - C12N 5/0695: {Stem cells; Progenitor cells; Precursor cells} - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract It is herewith provided methods of obtaining circulating cancer cells (CCCs)-enriched cellular populations based on the removal of CD45-positive cells from an apheresis product. It is also provided methods of obtaining circulating stem cells (CSCs)-enriched cellular population from a CCCs-enriched cellular population based on a selection either using the specific cellular markers or through culture. It is further provided methods of obtaining circulating tumor cells (CTCs)-enriched cellular population from a CCCs-enriched cellular population based on a selection using the specific cellular markers. It is also provided screening assays for the selection of (chemo)therapeutic agent as well as personalized medicine application based on drug sensitivity/resistance or cancer markers. ## Claims ### Claim 1 A method of providing a population of cells enriched in circulating cancer cells, the method comprising: a) depleting an apheresis nucleated cellular product from CD45-positive leukocytes to provide the population of cells enriched in circulating cancer cells; and b) collecting the population of cells enriched in circulating cancer cells. ### Claim 2 (depends on 1) The method of claim 1, further comprising: c) culturing the population of cells enriched in circulating cancer cells. ### Claim 3 (depends on 2) The method of claim 2, wherein step c) further comprises culturing the population of cells enriched in circulating cancer cells in non-adherent conditions. ### Claim 4 (depends on 3) The method of claim 3, wherein step c) further comprises culturing the population of cells enriched in circulating cancer cells in conditions allowing the formation of at least one mammosphere. ### Claim 5 (depends on 4) The method of claim 4, wherein the at least least one mammosphere comprises circulating stem cells and step c) further comprises collecting the at least one mammosphere to obtain a population enriched in circulating stem cells. ### Claim 6 (depends on 1) The method of claim 1, further comprising, prior to step b), selecting cytokeratin (CK)-positive cells from the population of cells enriched in circulating cancer cells. ### Claim 7 (depends on 6) The method of claim 6, wherein the population of cells enriched in circulating cancer cells is a population of cells enriched in circulating tumor cells and step b) further comprises collecting the population of cells enriched in circulating tumor cells. ### Claim 8 (depends on 1) The method of claim 1, further comprising, prior to step b), selecting epithelial cellular adhesion molecule (EpCAM)-positive-positive cells from the population of cells enriched in circulating cancer cells to obtain a population of cells enriched in circulating tumor cells and step b) further comprises collecting the population of cells enriched in circulating tumor cells. ### Claim 9 (depends on 1) The method of claim 1, further comprising, prior to step b), selecting CD24-negative and CD44-positive cells from the population of cells enriched in circulating cancer cells to provide a population of cells enriched in circulating stem cells, and, at step b), collecting the population of cells enriched in circulating stem cells. ### Claim 10 (depends on 9) The method of claim 9, further comprising, prior to step b) selecting aldehyde dehydrogenase isoform 1 (ALDH1)-positive cells and/or EpCAM-negative cells from the population of cells enriched in circulating cancer cells to provide the population of cells enriched in circulating stem cells. ### Claim 11 (depends on 1) The method of claim 1, further comprising, prior to step b), selecting CK-negative cells from the population of cells enriched in circulating cancer cells to obtain a population of cells enriched in circulating epithelial mesenchymal transition cells and, at step b), collecting the population of cells enriched in circulating epithelial mesenchymal transition cells. ### Claim 12 (depends on 11) The method of claim 11, further comprising, prior to step b), selecting vimentin-positive cells, E-cadherin-negative and/or N-cadherin-positive cells from the population of cells enriched in circulating cancer cells to obtain the population of cells enriched in circulating epithelial mesenchymal transition cells. ### Claim 13 (depends on 1) The method of claim 1, wherein the apheresis nucleated cellular product is from a subject having a cancer. ### Claim 14 (depends on 13) The method of claim 13, wherein the cancer is a melanoma or a carcinoma. ### Claim 15 (depends on 14) The method of claim 14, wherein the carcinoma is a breast carcinoma, a colorectal carcinoma, a prostate carcinoma or a lung carcinoma. ### Claim 16 (depends on 1) A population of cells enriched in circulating cancer cells obtained by the method of claim 1. ### Claim 17 (depends on 5) A population of cells enriched in circulating stem cells obtained by the method of claim 5. ### Claim 18 (depends on 7) A population of cells enriched in circulating tumor cells obtained by the method of claim 7. ### Claim 19 (depends on 9) A population of cells enriched in circulating stem cells obtained by the method of claim 9. ### Claim 20 (depends on 11) A population of cells enriched in circulating epithelial mesenchymal transition cells obtained by the method of claim 11.